TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24206058

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 433

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 433
Study: 22729014

Group type: EXPERIMENTAL
Intervention: Auricular acupressure combined with low-calorie diet
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham procedure combined with low-calorie diet
Number of subjects: 86
Study: 19817718

Group type: EXPERIMENTAL
Intervention: Dexamethasone 9 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17513282

Group type: EXPERIMENTAL
Intervention: Goal setting intervention and nutrition education intervention in addition to the basic program
Number of subjects: 2311

Group type: COMPARATOR
Intervention: Basic program only (control group)
Number of subjects: 2311

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 2311
Study: 16182162

Group type: EXPERIMENTAL
Intervention: Conventional anesthesia with 2% lidocaine and epinephrine, 1:100,000
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gow-Gates anesthesia with 2% lidocaine and epinephrine, 1:100,000
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group with conventional anesthesia with plain 3% mepivacaine
Number of subjects: 18
Study: 12398829

Group type: EXPERIMENTAL
Intervention: Head-up tilt test (1 week later)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Head-up tilt test (2 weeks later)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Head-up tilt test (third test)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Head-up tilt test (negative response)
Number of subjects: 127
Study: 9867336

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%, b.i.d. or q.i.d.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.1%, q.i.d.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.2%, q.i.d.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.3%, q.i.d.
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 7657740

Group type: EXPERIMENTAL
Intervention: GnRH agonist [(imBzl)D‐His6, Pro9‐NEt]‐GnRH (D‐His) at doses of 0.01, 0.1, 1, and 10 micrograms/kg
Number of subjects: 12
Study: 2710253

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (placebo or standard care not specified)
Number of subjects: 50
Study: 972138

Group type: COMPARATOR
Intervention: Normal walking
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Limping (induced by a 0.5-cm wooden spike under the heel)
Number of subjects: 10
Study: 31109313

Group type: EXPERIMENTAL
Intervention: CHOP-R plus acalabrutinib for six cycles followed by acalabrutinib maintenance
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHOP-R for six cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHOP-R plus acalabrutinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 0
Study: 28236981

Group type: EXPERIMENTAL
Intervention: Tecemotide (930μg as lipopeptide) subcutaneously once weekly for 8 weeks, then every 6 weeks until disease progression or treatment withdrawal.
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo subcutaneously once weekly for 8 weeks, then every 6 weeks until disease progression or treatment withdrawal.
Number of subjects: 172
Study: 25200879

Group type: EXPERIMENTAL
Intervention: Aquatic exercise and pain neurophysiology education
Number of subjects: 62

Group type: COMPARATOR
Intervention: Aquatic exercise alone
Number of subjects: 62
Study: 23403268

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 8831

Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 8831
Study: 21788267

Group type: EXPERIMENTAL
Intervention: Conventional neurological therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Constraint induced therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Therapeutic climbing
Number of subjects: 44
Study: 19339558

Group type: EXPERIMENTAL
Intervention: High-flexion posterior cruciate-retaining total knee prosthesis
Number of subjects: 250

Group type: COMPARATOR
Intervention: High-flexion posterior cruciate-substituting total knee prosthesis
Number of subjects: 250
Study: 17163320

Group type: EXPERIMENTAL
Intervention: Magnification chromoendoscopy (MCE) with indigo carmine dye staining
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MCE
Number of subjects: 56

Group type: COMPARATOR
Intervention: Random biopsies
Number of subjects: 56
Study: 14510624

Group type: EXPERIMENTAL
Intervention: Medical treatment with negative inotropic agents (beta‐blockers, verapamil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical myectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous septal ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual chamber pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study: 11052410

Group type: EXPERIMENTAL
Intervention: Pemoline treatment (3 mg/kg/day, optimized dosing)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9074702

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (0.75, 1.5 and 3 pmol.kg-1.min-1 for 30 min each)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study: 7941677

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg b.i.d.)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nifedipine (20 mg b.i.d.)
Number of subjects: 27
Study: 3239425

Group type: EXPERIMENTAL
Intervention: Carbachol, 150 mg subcutaneously
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sham feeding
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fundic distension to a volume of 600 ml
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 16,16-dimethyl prostaglandin E2, 80 micrograms
Number of subjects: 6
Study: 30151941

Group type: EXPERIMENTAL
Intervention: Second course of intravenous immunoglobulins (IVIg) administered 1 week after the first course
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second course of intravenous immunoglobulins (IVIg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 0
Study: 28034536

Group type: EXPERIMENTAL
Intervention: Copper oxide-impregnated textiles
Number of subjects: 0
Study: 27479337

Group type: EXPERIMENTAL
Intervention: Splinted design with bar units
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unsplinted design with ball attachments
Number of subjects: 40
Study: 23839050

Group type: EXPERIMENTAL
Intervention: Irinotecan at dose level VI (240 mg/m²)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Irinotecan at dose level VII (260 mg/m²)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Irinotecan (overall treatment)
Number of subjects: 33
Study: 21963063

Group type: EXPERIMENTAL
Intervention: Pronase and bicarbonate (Group B)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Saline solution (Group A)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Pronase, bicarbonate, and simethicone (Group C)
Number of subjects: 183
Study: 18941779

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Paclitaxel/bcl‐xL AS‐ODNs
Number of subjects: 48

Group type: COMPARATOR
Intervention: bcl‐xL AS‐ODNs (control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Medium (control)
Number of subjects: 48
Study: 16482073

Group type: EXPERIMENTAL
Intervention: ALA-rich diet (6.8 g/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: EPA/DHA-rich diet (1.05 g EPA/day + 0.55 g DHA/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control diet (oleic acid-rich diet)
Number of subjects: 37
Study: 14872156

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic antagonists
Number of subjects: 0
Study: 11741055

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day for six weeks)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Radiation therapy (800 cGy within 72 hours post-surgery)
Number of subjects: 166

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 166
Study: 9438487

Group type: EXPERIMENTAL
Intervention: Loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 8426204

Group type: EXPERIMENTAL
Intervention: Teniposide (VM26)/Cytarabine (Ara‐C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Prednisone/Doxorubicin (PDN/DOX)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall treatment protocol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Treatment protocol
Number of subjects: 120
Study: 3315542

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg daily by mouth)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Frusemide (40 mg by mouth)
Number of subjects: 10
Study: 28677325

Group type: EXPERIMENTAL
Intervention: Sleep-restricted group (5 hours TIB for 5 nights)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (9 hours TIB for 5 nights)
Number of subjects: 59
Study: 27979028

Group type: EXPERIMENTAL
Intervention: 12 SQ-HDMI
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 6 SQ-HDMI
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 24136330

Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 μg once-daily
Number of subjects: 586

Group type: COMPARATOR
Intervention: FF 200 μg once-daily
Number of subjects: 586

Group type: COMPARATOR
Intervention: FP 500 μg twice-daily
Number of subjects: 586
Study: 22306007

Group type: EXPERIMENTAL
Intervention: E-mail invitations
Number of subjects: 270

Group type: COMPARATOR
Intervention: Postal invitations
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Reminders for both invitation methods
Number of subjects: 270
Study: 20026784

Group type: EXPERIMENTAL
Intervention: Torcetrapib (60 mg)
Number of subjects: 67867

Group type: COMPARATOR
Intervention: CETP single-nucleotide polymorphisms
Number of subjects: 67867
Study: 18670328

Group type: EXPERIMENTAL
Intervention: Ramosetron
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 94
Study: 16009841

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses with a +2.00 diopter (D) addition
Number of subjects: 469

Group type: COMPARATOR
Intervention: Single vision lenses
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses
Number of subjects: 469
Study: 12649629

Group type: EXPERIMENTAL
Intervention: Once-daily OROS methylphenidate (OROS MPH)
Number of subjects: 407
Study: 11000370

Group type: EXPERIMENTAL
Intervention: Lifting of the abdominal wall (L)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nonlifting of the abdominal wall (NL)
Number of subjects: 150
Study: 8851737

Group type: EXPERIMENTAL
Intervention: Spatial span task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading span test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interference paradigm in Experiment 2
Number of subjects: 0
Study: 8101589

Group type: EXPERIMENTAL
Intervention: Growth monitoring package (GMP) intervention villages
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Non-growth monitoring package (NGM) intervention villages
Number of subjects: 1100
Study: 2427840

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg daily for 2 weeks, then 400 mg daily for 2 weeks, and 600 mg daily for another 2 weeks for non-responders
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 30356303

Group type: EXPERIMENTAL
Intervention: Text classification using a Naive‐Bayes machine‐learning algorithm
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group of 54 randomly selected texts from other periods of Virginia Woolf's life
Number of subjects: 100
Study: 27422705

Group type: EXPERIMENTAL
Intervention: Percutaneous reduction, cannulated screw fixation and calcium sulfate cement (PR+CSC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Minimally invasive sinus tarsi approach and plate fixation (MISTA)
Number of subjects: 80
Study: 25151098

Group type: EXPERIMENTAL
Intervention: Autologous salvaged blood collected by Sangvia™ Blood Salvage System
Number of subjects: 164

Group type: COMPARATOR
Intervention: Allogeneic red cell concentrates
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusions
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Transfusion of autologous blood
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Pre-operative haemoglobin concentration
Number of subjects: 164
Study: 22873356

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 317
Study: 20018797

Group type: EXPERIMENTAL
Intervention: Transpalatal distraction (TPD) as a bone‐borne device
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hyrax appliance as a tooth‐borne device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no expansion appliances)
Number of subjects: 30
Study: 18412271

Group type: EXPERIMENTAL
Intervention: Combined PCI and optimal medical therapy (OMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crossover from OMT to PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Significant untreated ischemia
Number of subjects: 0
Study: 15997932

Group type: EXPERIMENTAL
Intervention: Acetone-based adhesive (Prime & Bond NT) with blotted dry technique
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Water-based adhesive (Syntac Single Component)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Water- and ethanol-based adhesive (Single Bond)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (overwet technique)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Air-dried for 30 seconds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Air-dried for 3 seconds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blotted dry
Number of subjects: 120
Study: 12900600

Group type: EXPERIMENTAL
Intervention: Xeroform dressing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Jelonet dressing
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Reharvested donor sites
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Reepithelialized donor-site epidermis
Number of subjects: 19
Study: 10385633

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily for 5 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8689882

Group type: EXPERIMENTAL
Intervention: Cilest
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Femodeen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Marvelon
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mercilon
Number of subjects: 100
Study: 1997850

Group type: EXPERIMENTAL
Intervention: Prednisone (40 to 0 mg per day for 8 days)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 93
Study: 6724077

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (plasma exchange)
Number of subjects: 7
Study: 30460483

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (SD)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sleep control (SC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Suppression (both groups)
Number of subjects: 51
Study: 30321201

Group type: EXPERIMENTAL
Intervention: Manual therapy including desensitization manoeuvres of the central nervous system (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgery (n = 60)
Number of subjects: 120
Study: 26725717

Group type: EXPERIMENTAL
Intervention: HPV detection in samples from enrollment, 6‐, 12‐, and 18‐month visits
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Incidence of new HPV infections
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Point prevalence of vaccine types HPV‐6,‐11,‐16, and ‐18
Number of subjects: 120
Study: 25409438

Group type: EXPERIMENTAL
Intervention: Topiramate (N=561)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Topiramate (N=86)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Placebo (N=561)
Number of subjects: 561
Study: 21992596

Group type: EXPERIMENTAL
Intervention: 10 mg/day S‐(‐)equol for 12 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 160
Study: 20055340

Group type: EXPERIMENTAL
Intervention: Bone-patella tendon-bone autograft
Number of subjects: 173

Group type: COMPARATOR
Intervention: Bone-patella tendon-bone allograft
Number of subjects: 173
Study: 18091270

Group type: EXPERIMENTAL
Intervention: DTI-based functional neuronavigation
Number of subjects: 238

Group type: COMPARATOR
Intervention: Routine neuronavigation (Control)
Number of subjects: 238
Study: 15810623

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg bid
Number of subjects: 323

Group type: COMPARATOR
Intervention: Omeprazole 20 mg bid
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Patients with antibiotic resistance
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Patients with smoking history
Number of subjects: 323
Study: 11999127

Group type: COMPARATOR
Intervention: Sodium caprate added during the second period of perfusion (100-200 min) at pH 6.0
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sodium caprate added during the second period of perfusion (100-200 min) at pH 7.4
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sodium caprate
Number of subjects: 6
Study: 10024084

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 7
Study: 8652974

Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum (HBC) 100 ml three times a day for 3 consecutive days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bovine colostrum (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum (HBC)
Number of subjects: 75
Study: 2181565

Group type: EXPERIMENTAL
Intervention: nifedipine (40 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: low salt diet (5 g of salt/day) and nifedipine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: low salt diet (5 g of salt/day), nifedipine and a salt supplement (6 g/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: unrestricted diet and nifedipine (40 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: unrestricted diet and medication
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: low salt diet (5 g of salt/day)
Number of subjects: 15
Study: 340334

Group type: EXPERIMENTAL
Intervention: Cimetidine therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 22
Study: 31914834

Group type: EXPERIMENTAL
Intervention: 40g low-fat milk powder + 63mg daidzein (daidzein group)
Number of subjects: 270

Group type: COMPARATOR
Intervention: 40g low-fat milk powder (placebo group)
Number of subjects: 270
Study: 30548230

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual psychosocial care (UPC)
Number of subjects: 164
Study: 28418102

Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg + mirabegron 25 mg (combined S5 + M25 group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg + mirabegron 50 mg (combined S5 + M50 group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: solifenacin 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: mirabegron 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: mirabegron 50 mg
Number of subjects: 0
Study: 25535020

Group type: EXPERIMENTAL
Intervention: Patient-specific guides
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard instrumentation
Number of subjects: 70
Study: 22782923

Group type: EXPERIMENTAL
Intervention: Access to full-text articles
Number of subjects: 77

Group type: COMPARATOR
Intervention: Access to abstracts-only
Number of subjects: 77
Study: 21094194

Group type: EXPERIMENTAL
Intervention: Eating rate of foods (g/min)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Eating rate
Number of subjects: 37
Study: 18677657

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1% cream
Number of subjects: 48

Group type: COMPARATOR
Intervention: Topical ketoconazole 2% cream
Number of subjects: 48
Study: 17557047

Group type: EXPERIMENTAL
Intervention: Various endoscopic therapies for GERD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical and laparoscopic management of GERD
Number of subjects: 0
Study: 15286958

Group type: EXPERIMENTAL
Intervention: SS (supplements both before and after surgery)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: CS (postoperative supplements only)
Number of subjects: 152

Group type: COMPARATOR
Intervention: CC (no nutritional supplements)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: SC (supplements only before surgery)
Number of subjects: 152
Study: 11150359

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.15 mg/kg/day for 3 days, followed by tapering over 7 days)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 9744982

Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pill (OCP)
Number of subjects: 3996

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 3996
Study: 7877205

Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg orally)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (20 mg orally)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined therapy with nadolol and isosorbide‐5‐mononitrate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg orally) followed by isosorbide‐5‐mononitrate
Number of subjects: 38
Study: 3411740

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147